Navigation Links
BASF and Monsanto Formalize Agreement to Develop Dicamba-Based Formulation Technologies
Date:1/20/2009

any: The Chemical Company. Its portfolio ranges from oil and gas to chemicals, plastics, performance products, agricultural products and fine chemicals. As a reliable partner BASF helps its customers in virtually all industries to be more successful. With its high-value products and intelligent solutions, BASF plays an important role in finding answers to global challenges such as climate protection, energy efficiency, nutrition and mobility. BASF has more than 95,000 employees and posted sales of almost euro 58 billion in 2007. BASF shares are traded on the stock exchanges in Frankfurt (BAS), London (BFA) and Zurich (AN). Further information on BASF is available on the Internet at http://www.basf.com.

Cautionary Statements Regarding Monsanto's Forward-Looking Information: Certain statements contained in this release are "forward-looking statements," such as statements concerning the company's anticipated financial results, current and future product performance, regulatory approvals, business and financial plans and other non-historical facts. These statements are based on current expectations and currently available information. However, since these statements are based on factors that involve risks and uncertainties, the company's actual performance and results may differ materially from those described or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, among others: continued competition in seeds, traits and agricultural chemicals; the company's exposure to various contingencies, including those related to intellectual property protection, regulatory compliance and the speed with which approvals are received, and public acceptance of biotechnology products; the success of the company's research and development activities; the outcomes of major lawsuits; developments related to foreign currencies and economies; su
'/>"/>

SOURCE Monsanto Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Monsanto Shareowners Reelect Board Members at Companys Annual Meeting
2. Monsanto Board Approves 10 Percent Dividend Increase
3. Monsanto Recognized as Top Biotechnology Employer by Science Magazine
4. Monsanto Sees Growing Opportunity for Biotech Traits Globally
5. New Insect Protection Technology From Monsanto Company Deregulated by USDA
6. Monsanto Announces Key Regulatory Approvals for Roundup Ready 2 Yield(TM) Soybeans; Product Remains on Track for 2009 Launch
7. Monsantos Industry-Leading Seed Position Creates Accelerated Biotech Trait Opportunity in Latin America
8. Monsanto Company and Mendel Biotechnology Announce Cellulosic Biofuels Collaboration
9. Monsanto Executives to Address Investor Conferences in February
10. National Academy of Sciences Recognizes Monsantos Chief Technology Officer for Development of Agricultural Biotechnology
11. Monsantos R&D Pipeline Set to Deliver Valuable Products to Farmers Well Into Next Decade
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... Leading regenerative veterinary medicine company, ... canine osteoarthritis stem cell product, currently under development for FDA approval. The product ... marketed in the US by Aratana. This product, termed AT-016, is an allogeneic ...
(Date:7/30/2015)... ST. LOUIS, July 30, 2015 ... period in 2014) , Reported sales were $697 ... of 2014.  Sales grew organically by 8%, and changes ... Recent acquisitions increased sales by 1%. , By ... 8% in Applied and 11% in SAFC Commercial. ...
(Date:7/29/2015)... 2015 Sanofi, un leader ... résultats pour le premier semestre 2015. Le Directeur ... Visionner l,interview vidéo et lire la ... Au sommaire de l,interview :  ... croissance - Diabète - ...
(Date:7/29/2015)... July 29, 2015  HealthSouth Corporation (NYSE: ... providers of post-acute healthcare services, offering both facility-based ... of operations for the second quarter ended June 30, ... characterized by strong volume growth in both segments ... said Jay Grinney, President and Chief Executive Officer ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15
... Sept. 26 Nastech,Pharmaceutical Company Inc. (Nasdaq: NSTK ... in New York City on Thursday, October 4, 2007,from ... Westin New York at Times,Square, on 270 West 43rd ... C. Quay, M.D., Ph.D., Chairman, President and,Chief Executive Officer ...
... CLEARWATER, Fla., Sept. 26 Advanced Bio-Technologies,Inc (ABT) is ... have been purchased by HealthEdge Investment Partners of Tampa,FL. ... CEO, commented, "This is a new stage,in the exciting ... up,sales and marketing in the USA, build the necessary ...
... Finance Corporation,one of the nation,s leading providers of ... it has finalized a $7 million secured loan,agreement ... be used,to support Othera,s goal to become a ... for,ophthalmology, oncology and inflammatory disease. "This is ...
Cached Biology Technology:Nastech to Host 2007 Analyst and Institutional Investor Day 2Nastech to Host 2007 Analyst and Institutional Investor Day 3Advanced Bio-Technologies Inc Announces Acquisition by HealthEdge Investment Partners, Tampa FL 2Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals 2
(Date:7/2/2015)... Research and Markets( ... "Natural Language Processing Market by Type (Rule-Based, ... & Image Recognition) - Worldwide Forecast to 2020" ... key vendors occupying the market are 3M, Apple, ... NetBase Solutions, SAS Institute Inc., Verint Systems among ...
(Date:7/2/2015)... July 2, 2015 Fingerprint Cards has ... FPC1145 and FPC1155 from the distributor World Peace Industrial Group ... distributors in Asia . Deliveries are planned ... will be used by smartphone manufacturers in Asia ... in the communicated revenue guidance of approximately 2,200 MSEK for ...
(Date:6/30/2015)... June 30, 2015 Genisphere announced ... CEO to help further develop Genisphere,s therapeutics capabilities and ... experience, having spent much of the last 25 years ... Baxter Bioscience, and Johnson & Johnson. Tom started his ... and Biotech Corporate Finance. He graduated from Dartmouth College ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... the spread of deadly strains of avian flu such ... and Warwick have found. The research shows that even ... the disease is likely to spread unless almost all ... in Nature journal, is the first to quantify how ...
... comprehensive scientific study of tiger habitats ever done finds that ... they were thought to a decade ago. The tigers ... , This landmark study, commissioned by the National ... by some of the world's leading tiger scientists at World ...
... of researchers led by Prof. Irun Cohen of the ... mechanism of a vaccine for Type 1 diabetes. The ... vaccine, which is currently in advanced stages of clinical ... which the immune system mistakenly attacks the body's own ...
Cached Biology News:Bird flu study highlights need to vaccinate flocks effectively 2New tiger report release: Tiger habitat down from just a decade ago 2The molecular mechanism of a diabetes vaccine revealed 2
Agar, 500 g. Noble Agar.Moisture: < 10%, ash: < 1.6%, EEO (-mr): < 0.450 (pH 8.4). Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Ms anti-Cyclophilin D...
... Intended to qualitatively ... in formalin-fixed, paraffin-embedded (FFPE) ... spreads, and cell preparations, ... Hybridization (CISH). Fluorescent In ...
Mouse GM CSF Construction Kit provides antigen affinity purified polyclonal capture and tracer antibodies, and antigen standard for development of approximately ten microplate assays....
Biology Products: